Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year High – Time to Buy?

Twist Bioscience Corporation (NASDAQ:TWST) shares hit a new 52-week high on Monday . The stock traded as high as $80.79 and last traded at $78.9580, with a volume of 233794 shares trading hands. The stock had previously closed at $76.17.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of Twist Bioscience in a report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 target price for the company. UBS Group set a $89.00 price objective on Twist Bioscience in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Guggenheim lifted their price objective on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Finally, Canaccord Genuity Group assumed coverage on Twist Bioscience in a research note on Monday. They issued a “buy” rating and a $90.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.60.

Twist Bioscience Stock Performance

The company has a market capitalization of $5.29 billion, a PE ratio of -63.87 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. The company has a 50 day moving average price of $60.98 and a 200 day moving average price of $48.30.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. During the same quarter in the previous year, the company earned ($0.66) EPS. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. Equities analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 4,000 shares of the business’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $60.00, for a total transaction of $240,000.00. Following the completion of the sale, the chief financial officer owned 118,694 shares of the company’s stock, valued at $7,121,640. This represents a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total transaction of $673,440.00. Following the sale, the director directly owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. This represents a 40.33% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 33,170 shares of company stock worth $1,948,964. 3.08% of the stock is owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the company. EdgePoint Investment Group Inc. boosted its holdings in shares of Twist Bioscience by 71.1% during the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after acquiring an additional 1,696,377 shares during the period. First Light Asset Management LLC boosted its holdings in shares of Twist Bioscience by 26.4% during the third quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company’s stock valued at $33,624,000 after acquiring an additional 249,850 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Twist Bioscience by 350.3% during the fourth quarter. SG Americas Securities LLC now owns 76,484 shares of the company’s stock valued at $2,426,000 after acquiring an additional 59,500 shares during the period. William Blair Investment Management LLC boosted its holdings in shares of Twist Bioscience by 6.0% during the third quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock valued at $116,564,000 after acquiring an additional 235,679 shares during the period. Finally, Rafferty Asset Management LLC raised its stake in Twist Bioscience by 51.0% during the 3rd quarter. Rafferty Asset Management LLC now owns 114,268 shares of the company’s stock valued at $3,216,000 after acquiring an additional 38,608 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.